FLT3 and acute myeloid leukemia: The chemical structures of DMC and EF-24 are shown in Figure 1A. To first evaluate the antileukemic potency of DMC compared to EF-24, we conducted a cell cytotoxicity test with a CCK-8 assay on a panel of AML cells, which represented different FLT3 and NRAS statuses (HL-60: FLT3-WT/NRAS-Q61L; U937: FLT3-WT/NRAS-WT; and MV4-11: FLT3-ITD/NRAS-WT).